CD33 and acute myeloid leukemia: Designed for acute myeloid leukemia (AML), Mylotarg binds to CD33-expressing leukemic blasts, is internalized, and releases calicheamicin in the lysosomes, triggering double-stranded DNA breaks and apoptosis.